Inhibition of podocyte-endothelial cell VEGF signaling, whether through genetic or pharmacological means, causes endotheliosis, thrombotic microangiopathy, and the narrowing of capillary lumen seen in patients with albuminuria receiving VEGF-targeted therapies [24]. The gene discussed is VEGFA; the disease is thrombotic microangiopathy.